The company’s ‘Systematic Growth factors-57 (SGF-57)’, is said to be effective due to cytokine and growth factors of KGF, SCF, IGF-1, VEGF, bFGF and rh-SOD; blended well to the consistency of optimized density for regulating hair loss and improving hair growth.
“Cytokine is proven by many medical journals to differentiate and proliferate hair cells, and control hair growth cycle,” the company states.
Since the launch of what AesMed claims was the 'world’s first hair loss treatment by using growth factors', back in 2008, SGF-57 has since been used in ten university hospitals equipped with hair loss treatment centers, dermatology and cosmetic surgery clinics for alopecia sufferers in Korea.
"In more than 600,000 cases for performing alopecia treatment, SGF-57 has been proven to show its outstanding effectiveness and safety without any side effects until now," say reps.
Recognised by peer reviewed journals..
Alopecia is one of the most common conditions to affect and even bother young people, though people of any age can be affected.
Compared to current treatments such as Finasteride and Dutasteride, Aesmed claims SGF-57 is becoming a much more effective treatment for men and women, "free from side effects widely arisen in the three treatments."
The ingredient has been covered by journals like 'The Journal of Dermatology', classified at a SCI level for a clinical study of SGF-57 for treating female alopecia.
“This clinical study is worth of notice for the world’s first paper in the SCI-leveled journal which verifies clinical effectiveness for alopecia treatment by cosmetics rather than medicines,” adds AesMed CEO, Joe.
AesMed specializes in the design and development of cosmetics and medical devices in South Korea, manufacturing and providing beauty products to departments of dermatology and cosmetic surgery, and university hospitals since 2007.
In association with universities, clinical centers and institutions, the company has developed verified and proven cosmeceutical products including SGF-57 for alopecia treatment based on its own advanced technologies.